Search “Ozempic and sex drive” and you will find people swearing the drug rescued their libido and people swearing it killed it. Both can be telling the truth, because the honest answer is that GLP-1 medications don’t act on sex drive directly — they act on your weight, and weight change pushes sexual function in different directions depending on who you are, how fast you are losing, and how you feel along the way. This guide separates what the evidence actually supports from what is anecdote, and keeps two very different things — desire and erections — clearly apart. Because the effect runs through weight loss rather than the specific molecule, everything here applies equally to tirzepatide (Mounjaro and Zepbound) and the other GLP-1 and GIP/GLP-1 drugs — the degree just tracks how much weight you lose.
The well-supported upside: weight loss, testosterone, and erections in men
The clearest, best-evidenced story is in men with obesity. Excess fat tissue lowers testosterone: adipose tissue is rich in aromatase, the enzyme that converts testosterone to estradiol, and obesity also alters sex-hormone-binding globulin (SHBG) and the hypothalamic-pituitary signaling that drives testosterone production — so heavier men, on average, run lower total testosterone.[1] The European Male Ageing Study, following middle-aged and older men over time, found that weight change actively modifies testosterone: men who gained weight saw testosterone fall, and men who lost weight saw it partly recover — the hormonal change tracked the body change.[2]
Because low testosterone and obesity both contribute to erectile problems, losing weight can move erectile function in the right direction. The landmark randomized trial here predates GLP-1 drugs but isolates the mechanism cleanly: in obese men with erectile dysfunction, a two-year lifestyle program that produced meaningful weight loss significantly improved erectile-function scores versus a control group, with about a third of the men regaining normal function.[3] A GLP-1 drug is, in effect, a more powerful lever on that same first domino — the weight. There is even direct GLP-1 signal: a small study adding liraglutide to standard care in diabetic, obese men with overt hypogonadism reported improved erectile function, consistent with the weight-and-testosterone pathway rather than any direct genital action.[4]
Women: weight loss and sexual function
The pattern extends to women, though the mechanisms differ. In an ancillary analysis of the Look AHEAD trial — women with type 2 diabetes randomized to an intensive lifestyle weight-loss intervention versus support and education — the weight-loss group showed better sexual function and a lower rate of sexual dysfunction over the first year.[5] Obesity and the insulin-resistant, PCOS-type physiology that often accompanies it are associated with sexual-function problems, and the weight loss GLP-1 drugs produce plausibly improves the same things lifestyle weight loss did in that trial. As with men, the gain is indirect — a benefit of losing weight, which the drug enables, not a sexual effect of the drug.
The downside and the mixed signals
Against that upside sits a genuine set of reports — people whose libido fell on a GLP-1. This is where the evidence thins out, and honesty requires saying so: there are no large, high-quality trials measuring GLP-1 drugs’ effect on desire as a primary outcome, and much of what circulates is anecdotal. A 2025 review of GLP-1 drugs and erectile function frames the question as genuinely two-directional — “friend or foe” — with the metabolic benefits on one side and unresolved questions on the other.[6] Several mechanisms could plausibly lower desire:
- Rapid calorie restriction. Very low energy intake and fast weight loss can suppress the reproductive hormonal axis and blunt libido independent of any drug — the body de-prioritizes sex drive under perceived scarcity.
- Fatigue and nausea. The common early GI side effects and reduced food intake leave some people simply feeling unwell or low-energy, which is not a libido-friendly state.
- Reduced reward. GLP-1 drugs dampen the reward and “wanting” circuitry around food; some people report a more general flattening of appetites and motivation, which could spill into sexual desire. This is a hypothesis, not an established effect.
- Body-image and relationship shifts. Major body change is psychologically and relationally complex, and can move desire in either direction.
Desire versus erections: don't conflate them
A great deal of confusion comes from collapsing two separate problems into one. Erectile function is largely a blood-flow and vascular question — the domain of PDE5 inhibitors and the metabolic/vascular health that weight loss improves. Libido is desire, a central nervous-system phenomenon driven by hormones, mood, and reward circuitry. A person can have strong desire and unreliable erections, or reliable erections and flat desire — and the fix is different for each.
| Question | Erections (blood flow) | Libido (desire) |
|---|---|---|
| What it is | Vascular response — getting and keeping an erection | Central drive to want sex |
| How weight loss helps | Improves vascular/metabolic health; raises testosterone | Higher testosterone can help; restriction/fatigue can hurt |
| Typical targeted tool | PDE5 inhibitors; treat the vascular cause | Centrally-acting options; address hormones, mood, reward |
| GLP-1's role | Indirect benefit via weight and testosterone | Genuinely two-directional — up or down by person |
If sexual function is the actual goal
Because GLP-1 drugs are not sexual-function treatments, the right move when sex drive or erections are the real problem is to use the tools built for it. For blood-flow and erection problems, see our rundown of ED treatment options, which covers the PDE5-inhibitor territory and how to think about it. For a desire-specific problem — low libido itself, not erections — one centrally-acting option is bremelanotide; our evidence review of PT-141 (bremelanotide) walks through what it does and what the data show. And if low testosterone turns out to be the driver, the testosterone-therapy evidence review is the place to start.
The honest bottom line
GLP-1 drugs like Ozempic don’t have a single, predictable effect on sex drive, because they don’t act on it directly — they act on weight, and the consequences cut both ways. The best-supported outcome is an upside in men with obesity: weight loss raises testosterone and tends to improve erectile function,[2][3] with a parallel signal for improved sexual function in women.[5] The downside — lower libido in some people from restriction, fatigue, and blunted reward — is reported but far less rigorously studied. Whatever you experience, keep desire and erections separate, and remember that if sexual function is the problem you actually want solved, the drug for that is not Ozempic. The weight loss is the engine of the benefits; the targeted sexual-health tools are a different toolbox. This is general educational information, not medical advice.